Treatment and Prevention of Age‐Related Macular Degeneration

Publisher： John Wiley & Sons Inc

E-ISSN： 2055-2335|34|1|53-57

ISSN： 1445-937x

Source： JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol.34, Iss.1, 2004-03, pp. : 53-57

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Prevention and Treatment of Age-Related Macular Degeneration: An Update for Pharmacists

By Marshall Leisa   Roach J. Michael  

The Consultant Pharmacist, Vol. 28, Iss. 11, 2013-11 ,pp. : 723-737

American Society of Consultant Pharmacists

Access to resources Recommend Favorite

Age-Related Macular Degeneration: Epidemiology and Optimal Treatment

By Lacour M.  

Drugs & Aging, Vol. 19, Iss. 2, 2002-02 ,pp. : 101-133

Adis International

Access to resources Recommend Favorite

New therapies for the treatment of age-related macular degeneration

By Sarrafizadeh R.   Trese M.T.  

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 3, 2000-03 ,pp. : 333-341

Informa Healthcare

Access to resources Recommend Favorite

The Burden of Age-Related Macular Degeneration

By Schmier Jordana K.   Jones Mechelle L.   Halpern Michael T.  

PharmacoEconomics, Vol. 24, Iss. 4, 2006-01 ,pp. : 319-334

Adis International

Access to resources Recommend Favorite

Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration

By Stewart Michael W  

Expert Review of Clinical Pharmacology, Vol. 6, Iss. 2, 2013-03 ,pp. : 103-113

Informa Healthcare

Access to resources Recommend Favorite